SureGene conducts research with an eye toward partnering our genetic discoveries with molecular diagnostics manufacturers, pharmaceutical companies, healthcare providers, and insurers. Our focus centers on licensing our patented genetic discoveries and know-how to partners, and also on conducting genetic research collaborations with payers, pharmaceutical companies, and molecular diagnostics manufacturers. Our technology and discoveries can be used to improve the product profile and safety of antipsychotic drugs as well as to develop new molecules based on unique biological pathways discovered in the course of our genetic research. In addition, we conduct select fee-for-service research collaborations.
SureGene’s most advanced genetic discovery is a novel biomarker that is being developed as a molecular diagnostic test to predict and direct optimal antipsychotic drug selection.
To inquire about business development opportunities, please contact Bill Massey at (502) 287-0225 or Bill.firstname.lastname@example.org.